Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that causes breathing difficulties, chronic cough, and mucus.

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

The 26,905 people who indicated experiencing these symptoms completed questionnaires ... and the other half to lung specialists and asthma/COPD educators (specially trained nurses or respiratory ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Pneumonia can lead to lasting lung damage, increase the risk of chronic respiratory conditions, and exacerbate existing ...

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...

Human Metapneumovirus (hMPV) can be deadly in extreme cases but unlike other similar illnesses, there is no vaccine for it.

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...